Compared to the vehicle-treated group, VEGFR-2-positive tumor vessels were reduced by 33.8% in the irinotecan-treated group, by 64.6% in the mABL001-treated group, and by 80% in the combination treatment group (Figure 3C). The gene discussed is KDR; the disease is neoplasm.